Labcorp Launches FDA-Approved Companion Diagnostic for Ovarian Cancer
Labcorp has announced the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic for identifying patients with platinum-resistant ovarian cancer eligible for Merck’s KEYTRUDA. The diagnostic aims to improve treatment outcomes by enabling quick patient identification for newly approved therapies.
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food…